• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

克罗维斯公司将与葛兰素史克公司合作开展CO-1686联合mek抑制剂治疗egfr突变肺癌病人。

  [复制链接]
24005 47 老马 发表于 2014-11-18 16:59:11 |

马上注册,结交更多好友,享用更多功能,让你轻松玩转社区。

您需要 登录 才可以下载或查看,没有账号?立即注册

x
克罗维斯公司将与葛兰素史克公司合作开展CO-1686联合mek抑制剂治疗egfr突变肺癌病人。
Clovis Oncology Enters into Oncology Clinical Trial Collaboration with GlaxoSmithKline
http://finance.yahoo.com/news/cl ... ical-220000767.html
Clovis Oncology, Inc. (CLVS) announced today that they have entered into a clinical trial collaboration with GlaxoSmithKline LLC to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). The Phase 1/2 trial of rociletinib given in combination with trametinib is planned to start in 1H 2015. The trial is designed to assess the safety and activity of the combination in patients with EGFR mutant NSCLC who were previously treated with an EGFR tyrosine kinase inhibitor (TKI).

“We have seen significant activity in EGFR mutant NSCLC patients treated with rociletinib monotherapy, and so an important next step in our research is to examine rociletinib in combination with other targeted therapies that may also impact acquired resistance to EGFR inhibitors,” said Lecia V. Sequist, MD, MPH, Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School and the lead investigator for this combination study.

“As we continue to see compelling activity for rociletinib single-agent therapy at our selected dose, we look forward to exploring combination trials in both T790M-positive and T790M-negative patients,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “We believe that given the tolerability profile of rociletinib, particularly its lack of cutaneous toxicity, it may be a good candidate for combination therapy with trametinib, and other relevant targeted therapies. We intend to announce additional combination studies over the next few months.”

All patients with EGFR mutant NSCLC eventually develop resistance to EGFR TKI therapy and T790M is the primary resistance mutation1, occurring in 60 percent of patients treated with first- and second-generation EGFR inhibitors. Rociletinib targets the activating mutations of EGFR (L858R and Del19) and the T790M mutation, and has demonstrated encouraging clinical activity and tolerability in Phase 1/2 studies of patients with EGFR mutant NSCLC.

Another mechanism of acquired resistance in EGFR mutant NSCLC is through the activation of the mitogen-activated protein kinase (MAPK) pathway2. Trametinib is an orally active inhibitor of mitogen-activated protein kinase (MEK), which plays a key role in downstream MAPK pathway signaling, and it thereby inhibits growth factor-mediated signaling and cellular proliferation. Trametinib as a single agent has been approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.

In preclinical models of T790M+ EGFR mutant NSCLC, acquired resistance to T790M inhibitors can occur through MAPK pathway activation3, and the combination of rociletinib and trametinib has been shown to restore MAPK pathway suppression, resulting in increased anti-tumor activity.

This clinical trial is designed to test the hypothesis that the combination of two oral drugs targeting different cellular growth pathways, both often active in EGFR mutant NSCLC, will lead to augmented clinical benefit. Rociletinib is the core drug of the combination, and trametinib will be titrated in to first assess safety and then explore efficacy. Extensive tumor sampling will be performed to enable detailed molecular characterization of each patient’s tumor load, together with pharmacodynamic assessment of pathway inhibition. Integration of clinical data with molecular tumor data, both on and off drug(s), will enable robust understanding of observed clinical outcomes.
个人公众号:treeofhope

49条精彩回复,最后回复于 2015-6-23 00:12

无悔  高中一年级 发表于 2014-11-18 17:47:20 | 显示全部楼层 来自: 江苏苏州
9291耐药者值得关注,希望传来好消息。
新咖啡男人  大学二年级 发表于 2014-11-18 18:17:06 | 显示全部楼层 来自: 山东烟台
明明是1686  怎么说9291呢
一步错步步错  大学二年级 发表于 2014-11-18 21:14:02 | 显示全部楼层 来自: 四川
是不是9291耐药可能是MET扩增导致。马哥总是带来好消息。

点评

并不是,文章主题是mek抑制剂,并不是met。  发表于 2014-11-19 23:58
新咖啡男人  大学二年级 发表于 2014-11-18 21:23:51 | 显示全部楼层 来自: 山东烟台
这方面的研究太少了啊
草船借箭  超级版主 发表于 2014-11-19 20:03:44 | 显示全部楼层 来自: 山东烟台
感谢老马继续关心论坛,广大病友的福音!
煎熬  初中一年级 发表于 2014-11-19 21:37:16 | 显示全部楼层 来自: 河南焦作
老马总是能给我们带来新的希望,谢谢!
开心船长  初中一年级 发表于 2014-11-19 22:45:48 | 显示全部楼层 来自: 山东东营
看来6244可以上了
只有夕陽  高中一年级 发表于 2014-11-20 03:12:46 | 显示全部楼层 来自: 香港
其实,早已有报导指出当第3代egfr抑制剂出现耐药,联用mek抑制剂可恢复前者药效;亦有坛友(不多)提出一样用药指导:「….. WZ4002产生耐药后,可以用WZ4002联合MEK药(比如AZD6244)对付。….」
老公天天开心  高中二年级 发表于 2014-11-20 07:56:15 | 显示全部楼层 来自: 加拿大
谢谢分享,不停有新药出来就一直有希望

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表